
    
      This trial is a multicenter, randomized, open and parallel controlled project designed for
      patients with acute pulmonary embolism requiring thrombolysis after anticoagulant therapy in
      high-risk and middle-high risk populations.

      For the first stage: Subjects who are qualified for the screening criteria according to the
      inclusion and exclusion criteria will be randomly assigned to low-dose test drugs, high-dose
      test drugs or reference drugs for thrombolytic therapy at a ratio of 1:1:1.

      For the second stage: Subjects who are qualified for the screening criteria according to the
      inclusion and exclusion criteria will be randomly assigned to rPA(test group)or rt-PA(control
      group) for thrombolytic therapy at a ratio of 1:1.
    
  